Marcus   Bosenberg, MD, PhD

Marcus Bosenberg, MD, PhD

Yale Cancer Center/Smilow Cancer Hospital

Anthony N. Brady Professor of Dermatology, Pathology and Immunobiology; Director, Yale SPORE in Skin Cancer; Director, Yale Center for Immuno-Oncology; Co-Leader, Cancer Immunology, Yale Cancer Center

Expertise: Cancer GeneticsSkin CancerDermatologyCancer Immunology

Marcus Bosenberg MD, PhD, is a physician scientist who directs a leading melanoma research laboratory, is Co-Leader of the Cancer Immunology Program of Yale Cancer Center, Director of the Yale Center for Immuno-Oncology, Contact PI of the Yale SPORE in Skin Cancer, Director of the Center for Precision Cancer Modeling, and is a practicing dermatopathologist at Yale Dermatopathology through Yale Medicine.
In his research, Dr. Bosenberg studies factors that regulate anti-cancer immune responses. His laboratory has developed several widely utilized mouse models in order to study how melanoma forms and progresses, to test new cancer therapies, and how the immune system can be stimulated to fight cancer. He works to translate basic scientific findings into improvements in cancer diagnosis and therapy. He has published over 200 peer-reviewed articles and is a member of the Yale Cancer Center Executive Committee.
Dr. Bosenberg mentors undergraduate, graduate, medical, and MD-PhD students in his laboratory, teaches at Yale School of Medicine, and trains resident physicians, fellows, and postdoctoral fellows.

Education & Training:
Research Fellow-Dana-Farber Cancer Institute (2002)
Fellow-Harvard Medical School Dermatopathology Training Program (2000)
Chief Resident-Brigham & Women's Hospital (1999)
Resident-Brigham & Women's Hospital (1998)
Research Fellow-University of Wisconsin (1996)
MD-Cornell University Medical College (1994)
PhD-Cornell University Medical College (1993)
BA-Cornell University (1986)

No Clipping

No Research/Citations

Yale Scientists Identify Immune Cells Critical for Immunologic Memory for Melanoma

Immune-checkpoint inhibitors have become the standard of care for patients with advanced melanoma to improve survival, but only some patients respond to this immunotherapy and have long-term benefits. The lack of a long-lasting response, researchers say, is related to failure of antitumor immunologic memory. Treatment options for advanced melanoma are limited for patients who do not respond to this type of therapy.
27-Jul-2023 12:30:36 PM EDT

No Quotes

Available for logged-in users onlyLogin HereorRegister

No Video

close
0.08575